INTAS BIOPHARMACEUTICALS ACQUIRES US–BASED BPD INC

India’s leading biopharmaceutical company, Intas Biopharmaceuticals Limited (IBPL) has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc.), based in Poway, California. With acquisition process underway, both companies are actively pursuing plans to work closely towards fulfillment of common business objectives in the area of Contract Research and Manufacturing Services (CRAMS). With agreement in the final stages of completion, the financials has been undisclosed and will be accordingly announced at a later stage.

The development will facilitate and assist Intas Biopharmaceuticals Limited’s foray in US market especially to expand its CRAMS business. With mutual understanding and agreement, DR. SCOTT M. BROWN shall continue as PRESIDENT AND CHIEF SCIENTIFIC OFFICER of BPD Inc. and Dr. Rajeev Datar shall be the new CHIEF EXECUTIVE OFFICER of BPD Inc.

Sharing the details of the development, DR. RAJEEV DATAR, said, “With Intas Biopharmaceuticals and BPD Inc. coming together, the two companies complement technical strengths of each other. Both the companies shall gain expertise from the synergies in technical areas like gene expression optimization, medium optimization cell culture/fermentation services, protein purification scale-up and analytical services thereby expanding the scope of CRAMS activities.”

Expressing his views on the development, DR. SCOTT M. BROWN, said, “We are pleased to become associates with Intas Biopharmaceuticals who are leaders in area of biologics in India. Jointly we compliment each other on technology front and we, at BPD Inc., are looking forward to jointly work with Intas Biopharmaceuticals in the area of R&D and explore new technology frontiers.”

Intas Biopharmaceutical’s venture into CRAMS business has opened up new vistas for R&D in biosimilars. DR. DHANANJAY PATANKAR, CHIEF TECHNICAL OFFICER OF INTAS BIOPHARMACEUTICALS LTD., has worked the technical evaluation of the business plan. Dr. Dhananjay Patankar, said, “IBPL has taken up CRAMS opportunity as a focus area with tremendous potential and are preparing to scale up the facilities. IBPL offers a unique business model for offshore clients and has competitive advantage in terms of developing new biotech products, technology transfer and contract manufacturing at committed costs, quality and time to create a competitive advantage for the client.”

Intas Biopharmaceuticals Limited
Plot No. 423/P/A/GIDC, Sarkhej-Bavla Highway
Moraiya, Tal: Sanand, Ahmedabad – 382 210 INDIA
Siddharth J. Baad
00912717660208
siddharth.baad@intasbiopharma.co.in

About Intas Biopharmaceuticals Limited
Since launch of biotechnology operations in May 2000, Research & Development, Manufacturing and Marketing of biopharmaceutical products, with a special focus on Oncology (Cancer), are major thrust areas for IBPL. The company is India’s first and only biopharmaceuticals manufacturing company to receive European Union – Good Manufacturing Practice (EU-GMP) certification. Today, Intas Biopharmaceuticals Limited is the sole manufacturer of Pegylated GCSF in India and markets under the brand name “NEUPEG”.

About Biologic Process Development Incorporated:
Based in Poway, California, BPD Inc. is a Contract Research Organization (CRO) offering diversified services in the area of Molecular Biology. The biotechnology corporation offers wide range of R&D services including Express optimization, cell culture, bacterial fermentation, early-stage consulting services. Headed by Dr. Scott M. Brown, it offers experience in cloning expressing heterologous genes in microbial and non-microbial systems as well as protein purification from native and recombinant sources.

This release was published on openPR.